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damage in the stenotic kidneys in mice with
renovascular hypertension
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and Elisardo C Vasquez1,4*Background: Oxidative stress and DNA damage have been implicated in the pathogenesis of renovascular
hypertension induced by renal artery stenosis in the two-kidney, one-clip (2K1C) Goldblatt model. Considering our
previous report indicating that the chronic blockade of phosphodiesterase 5 with sildenafil (Viagra®) has marked
beneficial effects on oxidative stress and DNA damage, we tested the hypothesis that sildenafil could also protect
the stenotic kidneys of 2K1C hypertensive mice against oxidative stress and genotoxicity.
Methods: The experiments were performed with C57BL6 mice subjected to renovascular hypertension by left renal
artery clipping. Two weeks after clipping, the mice were treated with sildenafil (40 mg/kg/day for 2 weeks,
2K1C-sildenafil group) or the vehicle (2K1C). These mice were compared with control mice not subjected to renal
artery clipping (Sham). After hemodynamic measurements, the stenotic kidneys were assessed using flow cytometry
to evaluate cell viability and the comet assay to evaluate DNA damage. Measurements of intracellular superoxide
anions and hydrogen peroxide levels as well as nitric oxide bioavailability were also obtained.
Results: Sildenafil treatment significantly reduced mean arterial pressure (15%), heart rate (8%), intrarenal
angiotensin II (50%) and renal atrophy (36%). In addition, it caused a remarkable decrease of reactive oxygen
species production. On the other hand, sildenafil increased nitric oxide levels relative to those in the nontreated
2K1C mice. Sildenafil treatment also significantly reduced the high level of kidney DNA damage that is a
characteristic of renovascular hypertensive mice.
Conclusions: Our data reveal that sildenafil has a protective effect on the stenotic kidneys of 2K1C mice,
suggesting a new use of phosphodiesterase 5 inhibitors for protection against the DNA damage observed in the
hypoperfused kidneys of individuals with renovascular hypertension. Further translational research is necessary to
delineate the mechanisms involved in the prevention of renal stenosis in the clinical setting.
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Renal artery stenosis, the main cause of chronic renovas-
cular disease, is associated with significant metabolic
alterations in the kidney, such as increased renin syn-
thesis and reduction of nitric oxide (NO) sensitivity and
cGMP content [1,2], apoptosis and atrophy [3,4]. Recently,
it has become evident that oxidative stress is one of the
most important mechanisms involved in renal hypoper-
fusion. Oxidative stress may progressively impair renal
function and contribute to irreversible renal damage
[5,6]. Strategically, new pharmacological approaches have
been developed that include vasodilators (e.g., atrial natri-
uretic peptide and low-dose dopamine), antioxidant en-
zyme mimetics and novel antioxidants [7,8]. However,
these approaches have been unsuccessful in the clin-
ical setting.
In the 1930s, a canine experimental model of unilat-
eral renal artery stenosis (hypoperfusion), termed the
2K1C Goldblatt renovascular hypertension model, was
developed. The model involved partially clipping the left
kidney artery. Our laboratory has contributed to the
understanding of the pathophysiology of renovascular
hypertension using this model in rats since the 1990s
[9-12] and more recently in mice [13-19]. It is an in-
teresting disease model given the excessive production
of oxidative stress, which can be explained by two major
factors. First, endogenous activation of the renin secre-
tion system results in augmented levels of plasma [3,18,19]
and intrarenal [20,21] angiotensin II which is a po-
tent stimulus for NADPH oxidase-induced reactive
oxygen species (ROS) generation [6,22]. Second, based on
experimental studies of ischemia/reperfusion injury, clip-
induced hypoperfusion could result in microvascular
damage characterized by oxidative stress-induced tis-
sue injury, particularly when toxic oxidative species are in-
volved [23,24].
In this context, alternative pharmacological strategies
could be used to reduce oxidative stress and prevent
molecular damage in the kidney. Recent data from our
laboratory and others have indicated a potential appli-
cation for sildenafil, a phosphodiesterase type 5 (PDE5)
inhibitor, in many experimental models of diseases in
addition to erectile dysfunction and pulmonary hyperten-
sion [25-28]. We have previously demonstrated that, in
the atherosclerotic mice model, sildenafil reduces oxi-
dative stress and increases NO bioavailability, which cul-
minate in the protection against DNA damage [27,28].
However, the sildenafil’s efficacy in the treatment of
chronic stenotic kidney in the renovascular hypertension
model has not yet been investigated.
Therefore, the present study was designed to test the
hypothesis that sildenafil decreases stenotic kidney dam-
age in renovascular hypertensive mice by reducing oxi-
dative stress and increasing NO bioavailability.Methods
Animals
Experiments were performed in male wild-type (WT)
mice (C57BL/6) that weighed 23 g on average (12-week-
old). Mice were bred and maintained in the Laboratory
of Translational Physiology animal facility (Vitoria, ES,
Brazil) and were fed a standard chow diet and received
water ad libitum. Animals were housed in individual plas-
tic cages with automatic controlled temperature (22°C)
and humidity (60%) and were exposed to a 12/12 h light–
dark cycle. All of the experimental procedures were per-
formed in accordance with the National Institutes of
Health (NIH) guidelines, and the study protocols were ap-
proved by the Institutional Animal Care and Use Commit-
tee (CEUA-EMESCAM Protocol # 02/2013).
Induction of 2K1C renovascular hypertension and
treatment
The 2K1C angiotensin-dependent hypertension was in-
duced as previously described [3,13,15,17] and recently
reviewed by Campagnaro et al. [17]. Briefly, animals
were anesthetized (91/9.1 mg/kg ketamine/xylazine, i.p.).
The left renal artery was exposed through a retroperi-
toneal flank incision and carefully isolated from the renal
vein, nerves, and connective tissues. Using an ophthal-
mic surgical microscope (Opto Eletronica SA, model SM
2002, Belo Horizonte, MG, Brazil), a U-shaped stainless
steel clip with a 0.12 mm wide opening was placed
around the renal artery near the abdominal aorta, which
decreased renal perfusion [16,17]. Two weeks after sur-
gery, animals were divided into two groups (8 to 10 ani-
mals per group): renovascular hypertensive mice treated
with vehicle (2K1C) and hypertensive mice treated with
40 mg/kg/day of the PDE5-inhibitor sildenafil (Viagra®)
for 2 weeks by oral gavage (2K1C-sildenafil). The effect-
iveness of this sildenafil dose was previously demon-
strated in studies on endothelial dysfunction and DNA
damage in our laboratory [27,28]. The dose was based
on the fact that sildenafil displays reduced oral absorp-
tion by pre-systemic hepatic metabolism and high wash-
out in mice [29]. Sham-operated mice were used as
control animals (Sham).
Hemodynamic measurements
Twenty-eight days after the 2K1C or sham operations, mice
were anesthetized with a combination of ketamine/xylazine
(91/9.1 mg/kg, i.p.), and a catheter (0.040 mm outer ×
0.025 mm inner diameters, MicroRenathane, Braintree
Science, Massachusetts, USA) was inserted into the right
carotid artery to take mean arterial pressure (MAP) and
heart rate (HR) recordings. The free end of the cath-
eter was tunneled under the back skin to the level of the
shoulder blades. Two days after the catheter placement,
hemodynamic measurements were performed in conscious,
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others [30] and standardized in our laboratory [13-17] as a
sufficient period for complete recovery from surgery. For
the MAP and HR recordings, the arterial catheter was
plugged into a disposable blood pressure transducer (Cobe
Laboratories, Colorado, USA) connected to a pressure
processor amplifier and data-acquisition system (MP100,
Biopac Systems, California, USA). At the beginning of the
experimental session, a period of approximately 30 min
was allowed for stabilization of cardiovascular parameters
before the measurement of basal MAP and HR values in
conscious mice (Acknowledge software, Biopac Systems,
California, USA).
Biochemical analysis of renal function
Mice were placed in metabolic cages for a 24-hour adap-
tation period followed by another 24-hour period for
biochemical analysis of urine. After, animals were eutha-
nized, and their blood was collected for creatinine and
urea measurements using commercial test kits (Bioclin®,
BH, Brazil). Proteinuria was measured in urine sam-
ples by spectrophotometry (SP-220, Bioespectro, SP, Brazil)
after endpoint reaction with a colorimetric kit (Sensiprot,
Labtest Diagnostica S.A., Sao Paulo, Brazil).
Measurements of angiotensin II in kidney tissue
Renal levels of angiotensin II were analyzed by HPCL.
Briefly, angiotensin peptides were extracted from the left
kidney sample homogenates and purified in Oasis C18
columns (Waters Corporation) previously activated with
methanol (5 mL), tetrahydrofuran (5 mL), hexane (5 mL),
methanol (5 mL) and water (10 mL). After activation, the
samples were applied to the columns, washed with water
and eluted in ethanol/acetic acid/water in the proportions
of 90/4/6. The eluates were dried, redissolved in 500 μL of
mobile phase A (5% acetonitrile in 0.1% phosphoric acid),
filtered and injected into the HPLC system. Angiotensin
peptides we analyzed by reversed-phase ODS Aquapore
300 (250 x 4.6 mm) HPLC column, 7 μm particle size
(PerkinElmer’s Brownlee Columns), using the gradient
5–35% of mobile phase B (95% acetonitrile in 0.1% phos-
phoric acid) under a flow of 1.5 mL/min for 40 min.
The angiotensin peptides were identified according to
retention time (<6%) and peak height (<5%) of stand-
ard angiotensin peptides and normalized according to
kidney weight.
Cell samples and viability assay for flow cytometry
Kidney cell-enriched fractions from the kidneys of the
mouse groups were prepared based on previous studies
[31-33]. The left kidney was grossly triturated using sur-
gical scissors and incubated with an extraction solution
containing proteinase K (Sigma-Aldrich, St. Louis, MO,
USA) and collagenase type II (Gibco Life Technologies,Sao Paulo, SP, Brazil) to dissociate the cells. The cell extract
was filtered through a nylon screen (BD Falcon 70 μm) to
remove the cell debris; the samples were washed twice in
phosphate-buffered saline (PBS) and stored at −80°C until
further analysis.
Cell viability was assessed by propidium iodide (PI) ex-
clusion. A total of 106 cells were incubated with 2 μL of
PI for 5 min in the dark at room temperature. Then,
cells were washed with PBS and analyzed with a FACS-
Canto II flow cytometer (Becton Dickinson). For viability
quantification, samples were acquired in triplicate, and
10,000 events were used for each measurement. Cells
were excited at 488 nm, and PI fluorescence was de-
tected using a 585/42 bandpass filter. Data are expressed
as the percentage of unstained/viable cells [34].
Measurement of intracellular reactive oxygen species
The ROS analysis was performed by flow cytometry as
previously described [18,19,35]. Dihydroethidium (DHE)
and 2′,7′-dichlorofluorescein diacetate (DCF-DA) were
used to detect intracellular •O2
– and H2O2, respectively.
Given its ability to freely permeate cell membranes,
DHE has extensively been used to monitor •O2
– produc-
tion. Upon reaction with •O2
–, DHE is rapidly oxi-
dized to form ethidium, a red fluorescent product that
intercalates DNA and amplifies the red fluorescence sig-
nal. DCF-DA is a cell permeant indicator of H2O2 pro-
duction that is nonfluorescent until oxidation occurs
within the cell, which converts DCF-DA into the fluor-
escent form, which remains trapped in the cell. DHE
(160 mM) and DCF-DA (20 mM) were added to cell
suspensions (106 cells), which were then incubated at
37°C for 30 min in the dark, to determine the intracellu-
lar •O2
– and H2O2 concentrations, respectively [35].
Samples that were treated with 10 μM doxorubicin or
50 mM H2O2 for 5 min to create oxidative stress with-
out cell toxicity, were used as the positive control. Cells
incubated with ethanol were used as the negative control.
The NO measurements were performed as previously de-
scribed [36]. Briefly, the NO-sensitive fluorescent probe
4,5-diaminofluorescein-2 diacetate (DAF-2/DA: 2 μM)
was added to the cell suspension (106 cells), and the cells
were incubated at 37°C for 180 min in the dark. Samples
were treated with 10 μM sodium nitroprusside for the
positive control. Cells were then washed, resuspended in
PBS, and maintained on ice for immediate detection by
flow cytometry (FACSCanto II, Becton Dickinson, San
Juan, CA, USA). Data were analyzed using the FACSDiva
software (Becton Dickinson), and overlay histograms were
constructed using the FCS Express software. For fluores-
cence quantification samples were acquired in duplicate,
and 10,000 events were used for each measurement. Cells
were excited at 488 nm, and DHE, DCF and DAF fluores-
cence were detected using 585/42 (DHE) and 530/30
Dias et al. Journal of Translational Medicine 2014, 12:35 Page 4 of 11
http://www.translational-medicine.com/content/12/1/35(DCF and DAF) bandpass filters. Data were expressed as
the geometric mean fluorescence intensity (MFI).
Measurement of oxidized DNA by the alkaline comet
assay
The DNA damage was assessed using alkaline single cell
gel electrophoresis (the alkaline comet assay). The tech-
nique was performed using established protocols from our
laboratory [18,19,28,35] that were based on those of Singh
et al. [37] with minor modifications. Given the thermo-
and photo-sensitivity of the assay, the alkaline comet
assay was performed under low brightness and con-
trolled temperature.
The comet assay is a well-validated technique for DNA
damage measurements in individual cells. In brief, histo-
logical slides were precoated with 1.5% normal melting
point agarose. Subsequently, 20 μL of the cell suspen-
sion (containing 104 cells) was embedded in 100 μL
of 0.5% low melting point agarose and spread on agarose-
precoated slides using coverslips. After agarose gelling, the
coverslips were removed, and the slides were immersed in
freshly prepared lysis solution (2.5 M NaCl, 100 mM
EDTA, 10 mM Tris, 34 mM N-lauroylsarcosine sodium at
pH 10.0-10.5 with freshly added 1% Triton X-100 and
10% DMSO) for 1 hour at 4°C. Then, the slides were
placed in an electrophoresis chamber filled with freshly
prepared alkaline buffer (300 mM NaOH, 1 mM EDTA,
pH> 13) for 40 min at 4°C and electrophoresed at 300 mA
and 20 V for 30 min. Next, the slides were neutralized with
a 0.4 M Tris buffer (pH 7.5) for 5 min, washed with cold
distilled water and dried at room temperature for 1 hour.
The migration of DNA fragments toward the anode
creates a comet ‘tail’ that is visualized by staining with
ethidium bromide (20 μg/mL, Sigma-Aldrich). Images
were immediately obtained at 20× magnification using
a fluorescence optical microscope (Nikon Eclipse Ti,
Melville, NY, USA) equipped with excitation (510–550 nm)
and barrier (590 nm) filters. The coded images were ac-
quired using a CCD camera (Nikon) and analyzed with
the CASP program (public domain). Among several pa-
rameters provided by the program CASP, we used the per-
centage of DNA in the tail and the tail moment for
analysis of DNA damage. The images of 100 randomly
selected cells from each sample obtained from each
animal with two replicate slides were analyzed. During
the image analysis, comets without clearly identifiable
heads or comets with the majority of DNA localized to
the tail after electrophoresis were excluded as a quality
control parameter.
Statistical analysis
Data are presented as either representative figures or the
mean ± standard error of the mean (SEM). Flow cytometry
data are expressed as the geometric mean (GeomMean)fluorescence intensity or the percentage of stained cells.
The Kolmogorov-Smirnov test indicated that the variables
displayed a normal (Gaussian) distribution. The statistical
analysis was performed using one-way analysis of variance
(ANOVA). When significant differences were demon-
strated by ANOVA, the post hoc Bonferroni’s test was per-
formed. The statistical analyses were performed using the
Prism software (Prism 6.04, GraphPad Software, Inc., San
Diego, CA, USA). The differences were considered signifi-
cant when p < 0.05.
Results
Body and kidney weights, MAP and HR parameters
and angiotensin II levels
Initial body weight was statistically similar among the
groups. By the end of the experiments, only the 2K1C
group displayed reduced body weight. Twenty-eight days
after surgery, the left clipped kidney was atrophic, whereas
the right nonclipped kidney displayed compensatory hyper-
trophy in the 2K1C mice. Interestingly, sildenafil not only
reduced renal atrophy but also attenuated the compensa-
tory hypertrophy (Table 1 and Figure 2A). Figure 1 shows
the average values of resting MAP and HR measurements
in conscious animals 28 days after renal artery clipping.
As expected, the 2K1C mice showed higher MAP than
the Sham mice (125 ± 2 vs. 107 ± 2 mmHg, p < 0.01), and
the 2K1C mice treated with sildenafil showed MAP levels
(112 ± 2 mmHg) statistically similar to those observed in
the Sham mice (Figure 1A). The resting HR of the
2K1C mice was significantly higher than that in ob-
served in Sham mice and sildenafil treatment abolished
this tachycardia (Sham: 441 ± 10 bpm; 2K1C: 514 ± 7 bpm;
2K1C-sildenafil: 472 ± 15 bpm; p < 0.05) (Figure 1B).
Figure 2 (panel B) shows average values of intrarenal
angiotensin II in clipped kidneys in the 3 groups of ani-
mals. Angiotensin II levels in 2K1C mice were significantly
augmented when compared with Sham mice (179 ± 32 vs.
70 ± 7 pmol/g tissue, p < 0.01). The 2K1C mice treated
with sildenafil exhibited a reduction of 50% in these levels.
Renal function
The analysis of biochemical parameters showed that
after 28 days of renovascular hypertension the kidney
function was well preserved. We did not observe signifi-
cant differences in plasma creatinine (0.44 ± 0.07 vs.
0.40 ± 0.05 mg/dL), urea (65 ± 5 vs. 61 ± 2 mg/dL), pro-
teinuria (165 ± 23 vs. 145 ± 16 mg/dL/24 h) and the esti-
mated glomerular filtration rate (8.2 ± 1.1 vs. 7.6 ± 1.8 μL/
min) between groups. Sildenafil treatment did not modify
those parameters in 2K1C mice.
Cell viability assay
We evaluated the effect of clipping-induced stenosis on
renal cell viability using flow cytometry of PI-labeled cells.
Table 1 Body and kidney weights of Sham, 2K1C and 2K1C-sildenafil treated mice 28 days after renal artery clipping
Parameters Sham (n = 8) 2K1C (n = 10) 2K1C sildenafil (n = 8)
Body weight (g) 26 ± 0.5 24 ± 0.4* 26 ± 0.3#
Clipped kidney dry weight/body weight (mg/g) 1.63 ± 0.07 0.96 ± 0.17** 1.5 ± 0.04#
Nonclipped kidney dry weight/body weight (mg/g) 1.78 ± 0.04 2.02 ± 0.06* 1.77 ± 0.05#
Clipped kidney weight/nonclipped kidney weight ratio 0.91 ± 0.04 0.54 ± 0.09** 0.78 ± 0.06#
Kidney cell viability (%) 99 ± 0.13 94 ± 1.5** 98 ± 0.6#
Values are the means ± SEM. *p < 0.05 and **p < 0.01 compared with Sham group; #p < 0.05 compared with 2K1C group.
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2K1C group displayed reduced cell viability (Sham: 99 ±
0.13% vs. 2K1C: 94 ± 1.5%, p < 0.05), which was restored
with sildenafil treatment (98 ± 0.6% viable cells).
ROS production
ROS production was assessed using flow cytometry with
DHE, DCF-DA and DAF-2/DA to quantify the produc-
tion of •O2
–, H2O2 and NO, respectively. Typical histo-
grams from the flow cytometric analysis showed a
rightward-shift in the log of DHE (Figure 3A) and DCF
(Figure 3B) fluorescence in the 2K1C group compared
with the Sham group, contrasting with the results of the
2K1C-sildenafil group. Differently, the typical histogram
of NO production (Figure 3D), showed a rightward-shiftFigure 1 Sildenafil reduces arterial hypertension in renovascular
hypertensive mice. Resting mean arterial pressure (A) and heart
rate (B) values in conscious Sham (n = 8), 2K1C (n = 8) and
2K1C-sildenafil (n = 8) mice. Values are the means ± SEM. *p < 0.05
and **p < 0.01 (ANOVA).in the log of DAF fluorescence in the 2K1C-sildenafil
group compared with the Sham and 2K1C groups. As
shown in Figure 3C, the 2K1C mice exhibited a remark-
able increase (p < 0.05) in •O2
– (887 ± 41 a.u.) and H2O2
(308 ± 22 a.u.) levels compared with the Sham mice
(700 ± 21 and 214 ± 8 a.u., respectively). Sildenafil treat-
ment significantly decreased the •O2
– and H2O2 levels in
the stenotic and hypoperfused kidneys (765 ± 32 and
235 ± 20 a.u., p < 0.05). Figure 3 (panel E) shows aver-
age values of DAF fluorescence in the stenotic kidney
cells. Sham and 2K1C mice exhibited similar levels of
NO (215 ± 9 vs. 260 ± 22 a.u.). The 2K1C mice treated
with sildenafil displayed increased NO levels (1.7-fold,
p < 0.01).Figure 2 Sildenafil treatment decreases angiotensin II levels in
the stenotic kidney of renovascular hypertensive mice. Panel A:
typical photomacrograph showing the atrophy of the clipped (c)
kidney and the hypertrophy of the nonclipped (nc) kidney caused
by renal artery stenosis in the 2K1C mice compared with the Sham
mice. Images were obtained 28 days after the surgery. Scale bar:
5 mm. Panel B: bar graph shows augmented levels of angiotensin II
in the stenotic kidneys of the 2K1C group and the reduction of this
peptide by sildenafil. Values are the means ± SEM, n = 8 to 10 per
group. *p < 0.05 and **p < 0.01 (ANOVA).
Figure 3 Sildenafil ameliorates oxidative stress of the stenotic kidney cells in renovascular hypertensive mice. Representative flow
cytometry histograms show the fluorescence intensities of DHE (panel A), DCF-DA (panel B) and DAF-2/DA (panel D) stained cells from the
Sham (n = 10), 2K1C (n = 10) and 2K1C-sildenafil (n = 10) mice. Bar graphs show the geometric mean intensity of DHE (panel C, white bars) and
DCF-2/DA (panel C, color bars) and NO (panel E) production in the stenotic kidney. *p < 0.05 and **p < 0.01 (ANOVA).
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Figure 4A shows representative micrographs of the comets
obtained from the stenotic kidney cells of each group. The
images indicate no or minimal DNA fragmentation (0 and
1) in the Sham mice. In contrast, the representative images
from the 2K1C hypertensive mice indicate high (3 and
4) levels of genotoxicity. Mice treated with sildenafil
exhibited minimal DNA damage. Figure 4B shows the
average percentage of fragments in the tail of the comet,
which represents the degree of DNA damage in the 3
groups. The percentage of DNA in the comet tail repre-
sents the number of fragments that migrated during the
electrophoresis. The 2K1C group exhibited a 2-fold in-
crease in DNA fragmentation compared with the Sham
group. The 2K1C mice treated with sildenafil exhibited
minimal DNA damage, comparable to levels observed in
the Sham mice. The comet tail moment, an index of both
the migration of the genetic material and the relative
amount of DNA in the tail, was analyzed [38]. As shown
in Figure 4C, the cells from the stenotic kidney of 2K1Cmice showed a significant increase of the levels of DNA
damage compared with the Sham mice (52 ± 10 vs. 22 ±
3 a.u., p < 0.05). The DNA fragmentation in the cells iso-
lated from the mice treated with sildenafil (17 ± 4 a.u.) was
similar to the levels observed in the Sham group.
Discussion
The present study is the first to report that the chronic
inhibition of PDE5 with sildenafil decreases MAP, HR
and renal damage in renovascular hypertensive mice.
Beneficial effects of sildenafil include reduction of intrar-
enal angiotensin II and oxidative stress and enhanced
NO bioavailability as well as a subsequent improvement
of viability and a decrease of DNA damage in the sten-
otic kidney.
Current data indicate that •O2
– and H2O2 are signifi-
cantly increased in the pathophysiology of ischemic renal
diseases [39,40] and associated with DNA damage and
apoptosis in the outer cells of 2K1C hypertensive animals
[18,19]. Moreover, recent studies from our laboratory on
Figure 4 Sildenafil restores DNA integrity of the stenotic kidney cells in renovascular hypertensive mice. Panel A: Typical comets
showing higher DNA fragmentation in the 2K1C hypertensive mice compared with the Sham mice and the beneficial effects of sildenafil in
decreasing the DNA fragmentation. Levels of genotoxicity according to the comet tail size: 0 (intact comets), 1 (1% - 25% damage),
2 (26% - 45% damage), 3 (46% - 70% damage) and 4 (more than 70% damage). Scale bar: 10 μm. Bar graphs showing the mean percentage of DNA in
tail (panel B) and the mean of the tail moment (panel C). Values are the means ± SEM, n = 10 per group. *p < 0.05 (ANOVA).
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sildenafil exhibits antioxidant effects, thereby preventing
DNA damage in the liver and mononuclear cells [28].
These results strongly support the hypothesis that ROS
play an important molecular role in renal and cardiovascu-
lar diseases (e.g. ischemic diseases, hypertension, athero-
sclerosis) [18,19,41]. Moreover, this self-perpetuating cycleleads to progressive target organ damage. Our rational for
the present study was that sildenafil could also have benefi-
cial effects on ROS in the clipping-induced stenotic kidney
in the 2K1C angiotensin II-dependent hypertension.
Cumulative evidence suggests that PDE5 inhibition may
be a suitable option for reducing arterial pressure in pri-
mary (essential) hypertension and may have additional
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tends this idea because it demonstrates sildenafil’s antihy-
pertensive properties as well as its ability to restore HR
and protect against renal damage under conditions of
hypertension. These results reinforce recent data that sil-
denafil is an interesting alternative treatment for the pri-
mary cause of secondary hypertension [2]. Regarding the
HR, previous studies from our laboratory showed that the
chronic inhibition of NO synthesis increases the central
sympathetic drive [43,44]. The present results emphasize
this hypothesis since an improvement of sensitization of
the NO/cGMP pathway by sildenafil has been reported
by Stegbauer et al. [2], which could contribute to the
normalization of HR. Considering the evidence that sil-
denafil crosses the blood–brain barrier and that PDE5 is
present inside the brain [45], we cannot rule out the possi-
bility that sildenafil could have a direct central influence
on sympathetic/parasympathetic drive. In fact, recent re-
sults in rats have shown an increased sympathetic drive
imposed on the cardiovascular system by sildenafil, which
was not mediated by baroreflex [46]. However, additional
studies are needed to evaluate this influence in mice.
It has been demonstrated that 2K1C hypertension is
mainly initiated by the activation of the renin-angiotensin
system rather than by impairment of renal function [3]. In
agreement with others [3,47,48], we did not observe sig-
nificant differences in serum parameters of renal function
between 2K1C and Sham mice, presumably due to a
compensatory increase in glomerular filtration rate,
which appears to be sustained by the contralateral (un-
clipped) kidney [49]. The novelty of our study includes the
finding that sildenafil provided a double beneficial effect
in this pathophysiology. First, by reduction of intrarenal
angiotensin II levels, which are normally augmented
in stenotic kidney [20,21], and second, by preserva-
tion of renal function. These studies contrast with other
experimental [5,50,51] and clinical studies of renovascular
hypertension [52,53], which have demonstrated that in-
hibitors of angiotensin system (ACE inhibitors or AT1
antagonists) caused impairment of renal function due
to the acute deterioration of the glomerular filtration
rate [51,54].
The above data reinforce the findings of Welch et al.
[5] who showed the antihypertensive effects of the anti-
oxidant tempol, which ameliorated the oxidative stress,
glomerular filtration rate and oxygen efficiency in the
clipped kidneys in rats. Those authors have shown that,
in contrast with the angiotensin II receptor blocker
candesartan, tempol primarily exhibited antihypertensive
properties without causing renal failure. Thus, we specu-
late that treatment targeting the correction of redox bal-
ance with sildenafil could also offer advantages over
angiotensin II receptor antagonism as indicated by our
finding that sildenafil decreases atrophy and increasescell viability in stenotic kidney possible by the mecha-
nisms described below.
Given the reduced blood flow to the clipped kidney,
oxygen deprivation and oxidative stress are unavoidable
[55,56]. In this context, ROS overproduction reduces NO
bioavailability in the renal vasculature via a scavenging ef-
fect and/or NOS uncoupling, leading to the increased pro-
duction of •O2
– and H2O2 [4,57-59]. The present study is
the first to measure NO bioavailability in renal tissue from
2K1C using DAF-2/DA, which is a widely specific method
for determination of NO levels in isolated cells from tis-
sues. In contrast with plasma [60], NO levels in the sten-
otic kidney of 2K1C mice were not decreased, probably
due to compensatory actions elicited by angiotensin II and
hypoperfusion. This hypothesis is corroborated by findings
from us and from others demonstrating an upregulation
of nNOS in clipped kidneys in the 2K1C model [1] and an
increase of renal eNOS activity in the angiotensin II infu-
sion model [61]. In contrast with studies in 2K1C rats, in
which sildenafil did not modify the low plasma NO levels
[60], here we are demonstrating that in stenotic kidney
from 2K1C mice sildenafil increases 1.7-fold the levels of
NO and reduces the overproduction of •O2
– and H2O2.
Sildenafil, a PDE5 inhibitor, is a promising therapeutic
alternative given that it prevents the breakdown of NO-
driven cGMP and upregulates iNOS and eNOS [25], al-
though it exerts protective effects in null mice for NOS
isoforms [65]. Additionally, sildenafil increases the en-
zymatic activities of superoxide dismutase, catalase and
glutathione peroxidase [28,62] as well as potentially re-
stores NOS functionality [63], thereby acting as a potent
vasodilator [27,64]. Our data show by the first time that
in the 2K1C angiotensin II-dependent hypertension, the
protective actions of sildenafil are not solely mediated
through a reduction in the known molecular mecha-
nisms of oxidative stress, but also through other path-
ways, including the reduction of intrarenal angiotensin II
levels and, thus, contributing to attenuation of NADPH
oxidase signaling [17,41]. Moreover, the increase in
cGMP inhibits NADPH oxidase expression and activity,
thereby reducing •O2
– and H2O2 production and conse-
quently enhancing NO bioavailability [27,64]. This no-
tion has also been corroborated by the present results
demonstrating the effectiveness of sildenafil in increasing
DAF expression (directly) and decreasing DHE/DCF and
arterial pressure (both indirectly). Therefore, the several
antioxidative properties of sildenafil may constitute add-
itional mechanisms for the augmentation of the NO-
mediated pathway in renovascular injuries.
Another novel finding of our study is the observation
that sildenafil treatment reduces DNA damage in the
stenotic kidney of renovascular hypertension mice, pos-
sibly by the same antioxidative mechanisms described
above. Using the comet assay, it was possible to assess
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even for a short time interval (2 weeks). This finding re-
inforces the idea that sildenafil prevents tissue damage
induced by oxidative stress as previously reported by our
lab [28] and others [66,67], thereby opening the possibil-
ity of translational studies investigating the protection of
DNA in hypoperfused organs in the clinic. For example,
many clinicians continue to identify patients with a pro-
gressive loss of kidney function despite restoring blood
supply to the kidney using suitable therapeutic inter-
ventions that immediately restore oxygen to tissues
(administering clot dissolving drugs or using balloon
catheters) [8,51,55,68]. Although this treatment is pri-
marily beneficial, the reoxygenation of ischemic tissues
has been shown to cause tissue damage or reperfusion in-
jury in a phenomenon known as the “oxygen paradox”. In
this phenomenon, ROS derived from reperfusion are
responsible for post-ischemic tissue injury [8,69], and
these molecules can damage cellular components, such as
DNA, proteins, and lipids [35,39,70], compromising kid-
ney integrity. Therefore, sildenafil may serve as an al-
ternative therapy for renovascular disease, expanding
the possibilities of unconventional use of PDE inhibi-
tors therapy in patients with diseases of the urogeni-
tal tract involving the NO/cGMP cascade [71].
Recent studies suggest that renal ischemia rapidly mo-
bilizes endothelial progenitor cells (EPCs), which provide
renoprotection in acute kidney injury [51,72-75]. How-
ever, others have shown that the pro-oxidant milieu
induced in the 2K1C model is accompanied by apop-
tosis, primarily of interstitial CD34+/KDR+ progenitor
cells. These cells are presumably recruited to participate
in kidney repair, thereby impairing renal self-regeneration
[74]. In addition, Aleksinskaya et al. [76] proposed that
hypertension impairs NO signaling in the bone marrow,
causing inadequate mobilization of stem/progenitor cells.
In this context, sildenafil seems to have a positive effect; a
recent report shows that a sildenafil dose similar to that
used in our study increases the number of bone marrow-
derived EPCs in situations where oxidative stress is in-
creased [77]. These EPCs may be involved in the reduc-
tion of ROS and apoptosis through cell therapy as recently
observed by our group [57,78]. In the present study, we
cannot reject the participation of EPCs in improving cell
viability and reducing DNA damage. Therefore, the NO/
cGMP pathway could constitute an attractive approach
to rescue EPC function, offering new insights into anti-
ischemic therapies.
Although our data have shown that sildenafil reduced
angiotensin II, ROS and DNA damage in the clipped
kidneys in 2K1C mice, a relative limitation of our study
is that we analyzed these parameters in the stenotic kid-
ney without differentiating possible differences between
medulla and cortex.Conclusions
These results emphasize the role of increased oxidative
stress in the pathogenesis of renal injury in renovascular
hypertension. Moreover, the study highlights the benefi-
cial effect of sildenafil in preserving stenotic kidneys.
Further investigations are needed to establish the feasi-
bility and efficacy of sildenafil in clinical settings of renal
hypoperfusion.
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